Background. Bacterial vaginosis is a risk factor for preterm birth. The various conventional methods for its diagnosis are laborious and not easily reproducible. Molecular quantification methods have been reported recently, but the specific risk factors they might identify remain unclear.
mostly unchanged [1] . Infection and dysbiosis are one target in the effort to stem this rise [2] . Bacterial vaginosis (BV), an imbalance or dysbiosis of the vaginal flora, is a cause of late miscarriage and preterm birth. Its prevalence varies highly according to risk factors and countries [3] . Its diagnosis also presents problems [4] . BV is suspected in cases of malodorous discharge or abnormal leukorrhea adherent to the vaginal walls, and clinical manifestations are used as the diagnostic criteria [5] . However, BV is asymptomatic in approximately 50% of cases [6] . The Nugent score on Gram stains is a diagnostic test that defines normal vaginal flora, BV, or intermediate abnormal flora [7, 8] . The complexity of this score limits its adoption, and its subjectivity requires that it be performed by experienced microbiologists to ensure consistency [4, 7, 9] . Moreover, it does not identify several bacterial morphotypes associated with BV, in particular, Atopobium vaginae, and it underestimates BV recurrence [4, 7, 9, 10] .
Fredricks et al, the first group to use molecular biology techniques to characterize vaginal flora, suggested the involvement of new bacterial species in BV [11] . Preliminary studies have shown that A. vaginae is associated with BV [11, 12] . A molecular tool developed by our team based on the quantification of A. vaginae and Gardnerella vaginalis is both highly sensitive and specific for the diagnosis of BV [4] . It also characterizes vaginal flora in better detail than the Nugent score; in our first study, it enabled us to reclassify 57% of intermediate flora samples as BV [4, 13, 14] . In another preliminary study, we showed that high concentrations of A. vaginae were associated with a decreased interval between preterm labor and delivery [15] .
Those results have encouraged us to quantify the vaginal flora during pregnancy and define the relations between the concentrations of several species of bacteria (A. vaginae, G. vaginalis, Lactobacillus species, and Mycoplasma hominis) and the risk of preterm birth or late miscarriage.
MATERIALS AND METHODS

Study Design
Study Participants This prospective multicenter study took place at 8 university hospitals across France. Women who were receiving prenatal care at or were admitted to one of these hospitals and met the inclusion criteria were invited to participate. The Group de Recherche en Gynecologie Obstetrique helped to organize and coordinate this study, which was registered at ClinicalTrials. gov (identifier NCT00484653) and funded by the national hospital clinical research program (Programme de Recherche Clinique, number 2007-A00069-44). The ethics committee, Comité de Protection des Personnes Sud Méditerranée V, approved this project (number 07.019). The medical staff providing obstetric care were blinded to the molecular polymerase chain reaction (PCR) results. Obstetricians were authorized to screen for vaginal infections in patients with symptoms or if they routinely performed this screening. Clinical data, results from these analyses, and any subsequent treatment were collected, together with pregnancy outcomes.
Inclusion Criteria
The inclusion criteria were maternal age >18 years, gestational age of >14 but <28 weeks of gestation, risk of preterm delivery due to a short cervix (cervix <25 mm, measured by vaginal ultrasound) or a history of preterm delivery or late miscarriage, health insurance coverage, and written informed consent. Exclusion criteria were multiple pregnancy, treated hypertension, fetal malformation, antiphospholipid syndrome, diabetes, preeclampsia, renal disease, any autoimmune disease, and antibiotic treatment within the previous 7 days.
After the first year of inclusion, we modified the protocol to facilitate recruitment, by extending the gestational age window to 34 weeks, increasing number of centers from 5 to 8, and offering women the opportunity to take their own vaginal samples, after we demonstrated that the results of these samples were reproducible [13] . The protocol was amended in February 2008 for these points.
Finally, participants were subsequently excluded if they withdrew their consent, if delivery outcome was unknown, or if PCR vaginal sample results were missing (either because vaginal samples were not taken or did not reach the laboratory).
Sample Size
The sample size was determined by applying the data obtained during our preliminary work [15] . If we assumed a 30% proportion of preterm births before 37 weeks, a sample size of 690 women should show a hazard ratio (HR) of approximately 3.3 for A. vaginae, at a power at 80%. Taking loss to follow-up and missing data (estimated at 20%) into account, we needed to include 820 women.
Bacteriological Analysis
Nugent Score
All vaginal smear samples were Gram stained by an automated stainer (model 7320 Aerospray Gram Slide Stainer, Wescor, Logan, Utah). The Nugent score was then used to classify each sample [8] .
Molecular Analyses
On arrival at the laboratory, each vaginal swab was transferred to a sterile tube containing 500 µL of Basal Medium Eagle (Invitrogen, Carlsbad, California). DNA was extracted from 200 µL of each homogenized vaginal suspension with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) [3] .
Quantitative molecular analyses targeted Lactobacillus species, A. vaginae, G. vaginalis, M. hominis, and a human albumin gene. Based on specific quantitative PCR (qPCR) assays and a serially diluted plasmid suspension containing all 5 DNA targets for the quantification, they used the Quantitect Probe PCR Kit mix (Qiagen) and a Stratagene MX 3000P (Agilent, La Jolla, California), as previously reported (European Patent Office, number 2087134) [3] . The DNA targets, primers, probe sequences, and oligonucleotides used for qPCR are shown in Supplementary Table 1. Human albumin was used as an internal control to verify DNA quality and the absence of PCR inhibitors. Negative controls (PCR mix) were also included in each PCR assay. The final data are reported as copies of microorganism DNA per 1 mL of vaginal suspension [4] .
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics version 20. Continuous variables are expressed as mean ± standard deviation (SD), and categorical variables reported as counts and percentages. Mean values were compared with the Student t test or the Mann-Whitney U test, and percentages were compared with the χ 2 test or Fisher exact test, as appropriate. The thresholds were chosen from the analysis of diagnostic effectiveness (accuracy) and are expressed as the proportion of correctly classified subjects among all subjects. Survival was estimated with the Kaplan-Meier method and curves for time to delivery according to vaginal load. Different vaginal concentrations of pathogenic agents were compared with the log-rank test. Cox proportional hazard models were used to determine HRs after adjustment for gestational age. Statistical significance was defined as P < .05.
RESULTS
Patients
Overall, the study included 813 women from July 2007 through April 2012. Their clinical data are summarized in Table 1 . Inclusions according to year and center can be found in Supplementary Table 2 . Twenty vaginal samples were not available for analysis, either because no vaginal sample was taken, despite the informed consent, or because it did not reach the laboratory; 793 vaginal samples were analyzed. The PCR could not be interpreted for 7 specimens, because the poor albumin quality control result suggested either potential PCR inhibitors or inadequate DNA extract quality (0.008%). Thus, 786 PCR analyses and 793 Nugent scores were available. Both PCR and Nugent score were available for 773 women. Finally, 9 women (6%) were lost to follow-up, with no information regarding gestational age at delivery, and were excluded from the final analysis. Overall, analyses were performed for 764 patients. Proportions are calculated with the available data, as data are missing for some variables for up to 2.1% of the women (Table 1 ).
The overall rate of preterm delivery was 29%. In all, 91 (12%) women had an obstetric history that included preterm delivery before 34 weeks of gestation, and 92 (13%) a history of late miscarriage before 22 weeks (Table 1) . Among these women, 122 also had a short cervix, and 20 a long cervix. All 622 women without this history had an ultrasound-measured short cervix.
Nugent Score and Molecular Diagnosis of BV
There was no overall association between the Nugent score (≥4 or ≥7) and preterm delivery (P = .897). The correlation between the Nugent score and the molecular analyses was excellent according to the previously established molecular classification of vaginal flora, A. vaginae (≥10 8 copies/mL), and/or G. vaginalis (≥10 9 copies/mL) [4] :
.92-.99). When we applied our previous molecular definition of BV [4] as A. vaginae ≥10 8 copies/mL and/or G. vaginalis ≥10 9 copies/mL, the rate of molecular BV was 9.16% (n = 70).
Of these 70 women, 17 also had a Nugent diagnosis of BV, and 39 women had a diagnosis of intermediate flora. Their clinical and biological data are reported in Table 2 . Fourteen women had normal Nugent scores with a final diagnosis of molecular BV. A high vaginal load of either or both of A. vaginae and G. vaginalis based on molecular diagnosis of BV was associated with preterm birth (HR, 3.9; 95% CI, 1.1-14.1; P = .031; Table 3 ). Microorganism threshold quantification and accuracy analysis of their performance according to gestational age are reported in Supplementary Tables 3 and 4 .
Molecular Quantification of A. vaginae
Atopobium vaginae levels were associated with preterm delivery (Figure 1 and Table 3 ). Among women with preterm birth before 22, 28, and 32 weeks, high, compared with lower, vaginal concentrations of A. vaginae were associated with a significantly shorter time to delivery.
Molecular Quantification of Other Bacterial Species
Among women with preterm birth, high loads of M. hominis were associated with significantly earlier delivery than lower loads. Neither low lactobacilli nor high G. vaginalis loads were associated with a reduced time to delivery ( Figure 1 and Table 3 ).
Multivariate Analysis
After multivariate analysis, A. vaginae levels ≥10 8 copies/mL remained significantly associated with delivery before 22 weeks of gestation (adjusted HR, 4.7; 95% CI, .2-17.6; P = .014). After adjustment, neither molecular diagnosis of BV nor M. hominis vaginal load was significant any longer, and neither was associated with a reduced time to delivery.
DISCUSSION
Our study shows microbial dysbiosis in the vaginas of pregnant women at risk of preterm birth. A high vaginal load of A. vaginae (DNA level ≥10 8 copies copies/mL) identifies a population at high risk of preterm birth. This risk is highest both early in gestation and for late miscarriages [16] . Our molecular tool is reliable and efficient, allowing precise identification and quantification of several microorganisms involved in vaginal flora anomalies [4] . The molecular tool is definitely more powerful than the Nugent score for identifying BV [4, 8] . Although there was no overall association between the Nugent score and preterm birth, we found an association between preterm birth and BV, defined according to our earlier molecular criteria for BV. Thus, the molecular tool is more accurate and powerful than the Nugent score for identifying this risk factor for preterm birth. The limitations of the Nugent score may have reduced the statistical power of previous trials testing screening and treatment during pregnancy and might explain their disappointing results [4, 8, 17] . The Nugent score should be replaced or completed by specific qPCR assays [4, 7] . Several bacteria species, including A. vaginae, G. vaginalis, Eggerthella, Prevotella, Clostridiales BVAB2, and Megasphaera type 1, are reported to be highly predictive for BV, but diagnostic accuracy is best for A. vaginae [4, 7, [18] [19] [20] . Lactobacilli depletion, combined with the presence of either G. vaginalis or A. vaginae, is also a highly accurate predictor of BV [7] . Our data clearly show that the quantification of A. vaginae alone identifies a population at high risk of preterm birth. The addition of G. vaginalis or M. hominis analyses raises the cost of the test without increasing its performance, but may improve characterization of the anomalies and their course under treatment [14, 21] . Mycoplasma hominis was identified in only 2 women in each group ( preterm and term birth) and was not significant after adjustment. Any conclusion about its association with preterm birth thus seems imprudent. This study has detected for the first time an association between preterm birth and a high load of A. vaginae (≥10 8 copies/ mL), rather than simply a correlation between preterm birth and BV (≥10 8 copies/mL) [4] . Atopobium vaginae is a grampositive facultative anaerobic bacterial species, first isolated from the vaginal flora in 1999; although it remains difficult to identify, it has been shown to be involved in cases of tuboovarian abscess, salpingitis, endometritis, and more recently in obstetric complications [10, [21] [22] [23] . Two isolates from amniotic membrane infections are listed in the culture collection at the University of Göteborg, Sweden, and 2 others have been obtained from pregnant women, with anaerobic blood culture bottles; one had spontaneous bacteremia [10] and the other, bacteremia after chorionic villus sampling with fetal loss [23] .
The presence of various microorganisms of the vaginal microbiota and the current lack of a strategy for isolating this bacterium may make it difficult to culture [10] . Its identification with traditional phenotypic tests is laborious [10] , and successful identification by matrix-assisted laser desorption/ionizationtime-of-flight mass spectrometry depends on the database content; 16S ribosomal RNA gene sequencing is sometimes required for accurate identification [10, 23] .
The association between preterm birth and A. vaginae may be very important, for as of now, no trials of either antibiotics or tocolytics during preterm labor have successfully and consistently prolonged pregnancy [1, 24] . Inadequate diagnosis, antibiotic resistance, and the presence of a polymicrobial biofilm adherent to the vaginal epithelium and including A. vaginae and G. vaginalis as its main components, have been suggested to explain the unsatisfactory results of previous treatments [17, 25] . Metronidazole and clindamycin are the first-line treatments for BV, but both failure and recurrence rates are high, reaching approximately 50% at 3 months [26] [27] [28] . Although A. vaginae has frequently been shown to be resistant in vitro to metronidazole, women with recurrent BV initially respond to antibiotic 8 copies/mL for Atopobium vaginae, lactobacilli, and molecular bacterial vaginosis diagnosis (A. vaginae ≥10 8 copies/mL and or Gardnerella vaginalis >10 9 copies/mL).
treatment with steep declines in concentrations of various bacteria, including A. vaginae [12, 21, 29] . These bacteria later reemerge, however. This recurrence suggests that antibiotic resistance may not be the important mediating factor and indicates potential synergy between bacterial species [26, 30] . Clindamycin is effective against A. vaginae but unfortunately also destroys lactobacilli, which maintain the normal vaginal ecosystem by producing lactic acid and other substances known to prevent development of opportunistic microorganisms [31, 32] . The lack of lactobacilli is also associated with a shorter time to delivery in our study. However, a recent meta-analysis has suggested that clindamycin early in pregnancy-before 22 weeks-reduces the rate of preterm birth <37 weeks [33] . The efficacy appears to be similar with either metronidazole or clindamycin, although lactobacilli restoration at 30 days is uncommon for both [26, 34, 35] . The addition of probiotics to correct the lack of lactobacilli has neither decreased recurrence rates [36] nor reduced preterm birth [37] . Few authors have tested other antibiotics active against A. vaginae, such as azithromycin and amoxicillin, to treat microbial dysbiosis during pregnancy. Amoxicillin was ineffective [38] . Erythromycin, a macrolide compound known to have antiinflammatory properties, was reported to reduce preterm birth when administered with metronidazole [33, 39] . Failure to eradicate reservoirs, leading to reinoculation from an exogenous or endogenous source not detected by the assays, might also explain the unsuccessful results of other treatments. Prolonged therapy seems to reduce recurrence rates, and more intensive antibiotic therapy might overcome the problem of persistence [34] . Culture and antibiotic susceptibility testing might enable better management.
The association between A. vaginae and BV is now established. Our study demonstrates an association between A. vaginae and preterm birth in this high-risk population, but it remains unclear whether A. vaginae is simply a marker of other vaginal anomalies in a complex polymicrobial condition or if it plays a direct pathogenic role alone or as part of a microbial imbalance. The transmissibility of BV suggests that it results from external contamination rather than an internal disequilibrium [9, 27, 34] . The inability to prevent recurrences reflects our lack of knowledge about its origins. The initial event that shifts anaerobic predominance remains enigmatic. Recurrences have been associated with same-sex partners, whether exclusive or not. Reduced rates, on the other hand, are associated with condom use and estrogencontaining oral contraceptives [9, 27, 34] . BV is uncommon in the absence of previous sexual contact [40] and has a high prevalence in lesbians [34] .
Our study has some limitations. First, only women at high risk for preterm birth were included; most of them had a short cervix without any previous history of preterm deliveries. Our results cannot be generalized and should be further assessed in general obstetric populations. Second, we did not test all the microorganisms known to be involved in BV and may have missed some other vaginal microbial imbalances. Third, the study is observational, and future clinical studies are needed to determine whether use of this molecular tool reduces preterm births. Finally, the gestational age range at inclusion was broad (14-34 weeks) . This is, however, less important in an observational study. Inclusion in future therapeutic trials should not occur after 20 weeks. The strengths of this study include extensive use of controls to check false-positive and false-negative results and the accurate bacterial quantification.
A high vaginal load of A. vaginae now appears to be associated with preterm birth in high-risk populations. It should be further evaluated in low-risk populations, to see whether its treatment might help prevent preterm birth.
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